Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Participants With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at Fresno, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Gilead Sciences
- Links
- Gilead Clinical Trials Website
- ID
- NCT04971785
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 440 study participants
- Last Updated